Mylan’s EpiPen Pricing Crossed Ethical Boundaries

By Daniel Kozarich, Senior Business Consultant at Vendavo

Here’s why the drugmaker should apologize to consumers.

As the CEO of the drug maker that sells the EpiPen allergy-reaction injector defended the company’s six-fold price increases before Congress last week, it’s appalling to see that Heather Bresch took no fault. The company’s price hikes on a life-saving drug is clearly unethical if we take a closer look.

EpiPen has gone from $100 for a two-pack in 2009 to $608 today. Usually, companies would be applauded for the ability to create revenue through such pricing power. But when it comes to life-saving drugs, consumers interpret these significant increases as the producer profiteering off a person’s life or death need.

Read More >>>


  • This field is for validation purposes and should be left unchanged.